$1.29
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Overview
52-week range
$0.87
$3.08
19% of range
Avg surprise (last 3)
+15.8%
Avg reaction (last 2)
-3.2%
50% positive
Latest IV / EM
1140%
EM ±47.6% · $2 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.17 | $-0.24 | +29.2% | +78.8% | +1.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.27 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.51 | $-0.59 | +13.6% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.80 | $-0.84 | +4.8% | — | -8.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.91 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.03 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.09 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.80 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.70 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.21 | -$0.51 | +58.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-13M | — | $-21M | $-21M | $-30M | — | $-34M | $-39M |
| Net income | $-12M | — | $-16M | $-21M | $-29M | — | $-33M | $-37M |
| EPS (diluted) | $-0.17 | — | $-0.27 | $-0.51 | $-0.80 | — | $-0.91 | $-1.03 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $45M | $56M | $47M | $56M | $36M | $58M | $88M | $113M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $46M | $58M | $49M | $65M | $45M | $68M | $94M | $116M |
| Total assets | $46M | $59M | $55M | $73M | $55M | $80M | $110M | $136M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $28M | $29M | $40M | $46M | $26M | $28M | $34M | $32M |
| Total equity | $19M | $30M | $16M | $28M | $29M | $52M | $76M | $104M |